AAVantgarde Bio, a clinical-stage,biotechnology company pioneering therapies for inherited retinal diseases (IRDs) has successfully closed a $141 million Series B financing round.

“This investment is a strong endorsement of our team, our science, and two clinical IRD programs,” said Dr. Natalia Misciattelli, CEO of AAVantgarde. “Both programs address the root genetic causes of devastating conditions and offer hope of improvement to patients and families living with progressive vision loss”

Please click here to read more